HIV-associated thrombocytopenia is rarely a serious clinical problem associated with impaired platelet production and increased obliteration in HIV infection.

What is the Pathology of HIV-Associated Thrombocytopenia?

The pathology of HIV-associated thrombocytopenia is:

-Etiology: The cause of HIV-associated thrombocytopenia is HIV infection.

-Genes involved: None.

-Pathogenesis: The sequence of events that lead to HIV-associated thrombocytopenia are as the result of diseased megakaryocytes prone to apoptosis, and diminished in terms of platelet production. HIV infection may cause dysregulation, and hyperplasia of B cells, which influence the advance of immune-mediated thrombocytopenia.

-Morphology: Rashes.

-Histology: Low platelet count.

How does HIV-Associated Thrombocytopenia Present? 

Patients with HIV-associated thrombocytopenia typically have no gender prevalence present at an age range of childhood and adulthood. The symptoms, features, and clinical findings associated with HIV-associated thrombocytopenia include platelet counts of less than 150,000/µL in clinical presentation, fever, hemolytic anemia, and neurologic and renal dysfunction.

How is HIV-Associated Thrombocytopenia Diagnosed? 

HIV-associated thrombocytopenia is diagnosed through platelet count. 

How is HIV-Associated Thrombocytopenia Treated? 

HIV-associated thrombocytopenia is treated through immune-based therapy.

What is the Prognosis of HIV-Associated Thrombocytopenia?

The prognosis of HIV-associated thrombocytopenia is fair. Respond fairly to immune-based therapy though associated with relapse.